20.67 USD
-0.1 (-0.48%)
21.08 USD
+0.41 (+1.98%)
We assign a fundamental rating of 6 out of 10 to PCRX. PCRX was compared to 191 industry peers in the Pharmaceuticals industry. While PCRX belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. PCRX is valued quite cheap, but it does not seem to be growing. These ratings would make PCRX suitable for value investing!
1. Profitability
1.1 Basic Checks
- In the past year PCRX was profitable.
- PCRX had a positive operating cash flow in the past year.
- Of the past 5 years PCRX 4 years were profitable.
- Each year in the past 5 years PCRX had a positive operating cash flow.
1.2 Ratios
- PCRX has a Return On Assets of 1.65%. This is amongst the best in the industry. PCRX outperforms 81.15% of its industry peers.
- PCRX has a Return On Equity of 2.95%. This is amongst the best in the industry. PCRX outperforms 82.20% of its industry peers.
- PCRX has a better Return On Invested Capital (3.63%) than 81.68% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for PCRX is significantly below the industry average of 12.83%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.65% | ||
| ROE | 2.95% | ||
| ROIC | 3.63% |
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.3%
ROIC(5y)4.55%
1.3 Margins
- With a decent Profit Margin value of 2.99%, PCRX is doing good in the industry, outperforming 79.58% of the companies in the same industry.
- PCRX has a better Operating Margin (8.88%) than 81.15% of its industry peers.
- PCRX's Operating Margin has improved in the last couple of years.
- The Gross Margin of PCRX (79.17%) is better than 84.29% of its industry peers.
- PCRX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.88% | ||
| PM (TTM) | 2.99% | ||
| GM | 79.17% |
OM growth 3Y-15.96%
OM growth 5Y11.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
2. Health
2.1 Basic Checks
- PCRX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- PCRX has less shares outstanding than it did 1 year ago.
- The number of shares outstanding for PCRX has been increased compared to 5 years ago.
- PCRX has a worse debt/assets ratio than last year.
2.2 Solvency
- An Altman-Z score of 1.86 indicates that PCRX is not a great score, but indicates only limited risk for bankruptcy at the moment.
- The Altman-Z score of PCRX (1.86) is comparable to the rest of the industry.
- The Debt to FCF ratio of PCRX is 3.03, which is a good value as it means it would take PCRX, 3.03 years of fcf income to pay off all of its debts.
- Looking at the Debt to FCF ratio, with a value of 3.03, PCRX belongs to the top of the industry, outperforming 90.58% of the companies in the same industry.
- A Debt/Equity ratio of 0.52 indicates that PCRX is somewhat dependend on debt financing.
- PCRX's Debt to Equity ratio of 0.52 is on the low side compared to the rest of the industry. PCRX is outperformed by 63.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 3.03 | ||
| Altman-Z | 1.86 |
ROIC/WACC0.46
WACC7.85%
2.3 Liquidity
- PCRX has a Current Ratio of 5.26. This indicates that PCRX is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Current ratio, with a value of 5.26, PCRX is in the better half of the industry, outperforming 64.92% of the companies in the same industry.
- A Quick Ratio of 3.78 indicates that PCRX has no problem at all paying its short term obligations.
- PCRX has a Quick ratio of 3.78. This is in the better half of the industry: PCRX outperforms 60.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.26 | ||
| Quick Ratio | 3.78 |
3. Growth
3.1 Past
- PCRX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.90%.
- The Earnings Per Share has been growing by 13.96% on average over the past years. This is quite good.
- The Revenue for PCRX has decreased by -16.85% in the past year. This is quite bad
- The Revenue has been growing by 10.73% on average over the past years. This is quite good.
EPS 1Y (TTM)-6.9%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-11.39%
Revenue 1Y (TTM)-16.85%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%6.49%
3.2 Future
- PCRX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.01% yearly.
- PCRX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.38% yearly.
EPS Next Y-5.84%
EPS Next 2Y4.39%
EPS Next 3Y6.17%
EPS Next 5Y7.01%
Revenue Next Year4.33%
Revenue Next 2Y6.28%
Revenue Next 3Y7.3%
Revenue Next 5Y6.38%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 6.96 indicates a rather cheap valuation of PCRX.
- Based on the Price/Earnings ratio, PCRX is valued cheaply inside the industry as 93.72% of the companies are valued more expensively.
- When comparing the Price/Earnings ratio of PCRX to the average of the S&P500 Index (27.21), we can say PCRX is valued rather cheaply.
- With a Price/Forward Earnings ratio of 5.91, the valuation of PCRX can be described as very cheap.
- Based on the Price/Forward Earnings ratio, PCRX is valued cheaply inside the industry as 93.72% of the companies are valued more expensively.
- PCRX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 24.26.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.96 | ||
| Fwd PE | 5.91 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, PCRX is valued cheaply inside the industry as 96.34% of the companies are valued more expensively.
- PCRX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. PCRX is cheaper than 95.81% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.16 | ||
| EV/EBITDA | 5.99 |
4.3 Compensation for Growth
- The decent profitability rating of PCRX may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.5
EPS Next 2Y4.39%
EPS Next 3Y6.17%
5. Dividend
5.1 Amount
- No dividends for PCRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
PACIRA BIOSCIENCES INC / PCRX FAQ
What is the ChartMill fundamental rating of PACIRA BIOSCIENCES INC (PCRX) stock?
ChartMill assigns a fundamental rating of 6 / 10 to PCRX.
What is the valuation status for PCRX stock?
ChartMill assigns a valuation rating of 8 / 10 to PACIRA BIOSCIENCES INC (PCRX). This can be considered as Undervalued.
How profitable is PACIRA BIOSCIENCES INC (PCRX) stock?
PACIRA BIOSCIENCES INC (PCRX) has a profitability rating of 7 / 10.
What is the valuation of PACIRA BIOSCIENCES INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for PACIRA BIOSCIENCES INC (PCRX) is 6.96 and the Price/Book (PB) ratio is 1.22.